AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios to Participate in March Investor Conferences

02 Mar 2023 07:26:35 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

02 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

08 Jan 2023 19:00:00 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

03 Jan 2023 16:57:50 By Nasdaq GlobeNewswire

Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

21 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

11 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition

10 Dec 2022 17:30:00 By Nasdaq GlobeNewswire

Agios Appoints Tsveta Milanova as Chief Commercial Officer

06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Agios to Participate in December Investor Conference

30 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

10 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

03 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty

27 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

20 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

26 Sep 2022 18:13:07 By Nasdaq GlobeNewswire

Agios Appoints Cecilia Jones as Chief Financial Officer

19 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

16 Sep 2022 05:41:44 By Nasdaq GlobeNewswire

Agios to Participate in September Investor Conferences

24 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

18 Aug 2022 17:35:00 By Nasdaq GlobeNewswire